After an overall miss, a subgroup showed a 2+ month survival gain; Pfizer is testing sigvotatug vedotin with Merck's Keytruda ...

Discover how the new personalized cancer vaccine intismeran combined with Keytruda lowers melanoma relapse risk, achieving an 82% 2-year survival rate.

Moderna's mFLUSIVA became the first FDA-approved mRNA flu vaccine for adults 50+, but its stock surge stems from cancer ...

Pfizer presented new data on sigvotatug vedotin, its lung cancer drug, after a failed Phase 3 trial, highlighting a 2.5-month survival benefit in a ...

The INTerpath-001 trial randomized 1,137 patients with resected stage IIB to IV melanoma to Keytruda alone or Keytruda plus ...

An experimental vaccine developed by Merck and Moderna could become the first vaccine of its kind used to treat cancer. Scientists hope it won’t be the last.

Moderna's stock plunged on Thursday, startling investors. But the company remains one of this year’s hottest biotech ...

Moderna gave investors a scare as its stock plunged on Thursday. But it's still one of the hottest biotechs this year. And it's hardly alone – the sector is on a roll and looks poised for more gains.

A study of a personalized vaccine combined with an existing immunotherapy found the treatment helped patients with melanoma avoid cancer recurrence. The combination trains the patient's immune system ...

When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each ...

Moderna is rated a Hold, citing valuation concerns, lack of definitive long-term efficacy data, and significant execution and ...

Moderna and Merck are preparing to seek regulatory approval after their experimental melanoma vaccine delivered promising ...